ClinicalTrials.gg
RecruitingNCT07534956Updated Apr 16, 2026

The Effect of Paedfusor TCI, Eleveld TCI, and Sevoflurane Anesthesia on Postoperative Awakening Agitation in Pediatric Patients

An interventional study of propofol ( Paedfusor Model) and propofol (Eleveld Model) in Emergence Delirium in Pediatric Anesthesia, Pediatric Anesthesia and Postoperative Agitations in Pediatric Patients, sponsored by Marmara University Pendik Training and Research Hospital. Recruiting at 2 sites in Turkey (Türkiye). Open to participants aged 3 Years to 10 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-16.

Sponsored by Marmara University Pendik Training and Research Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
3 Years to 10 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 96 studies in Postoperative Nausea and Vomiting with a site in Turkey — 22 open to participants now, 23 under way, none of them phase 3. Postoperative Nausea and Vomiting · Turkey.

Planned enrollment
13th of 71
150 · median 90
Started
2026
with 11 others
No phase
55 of 96
13 open now
Primary completion
2027-10
later than 22 of 22 live
Registered
87th of 96
by date

Among the 96 studies in Postoperative Nausea and Vomiting with a site in Turkey, this one is the 13th largest by planned enrollment of the 71 interventional ones that give a count, is one of 12 that started in 2026, is one of 55 with no phase, reaches primary completion later than 22 of the 22 other live ones, and was the 87th registered.

Postoperative Nausea and Vomiting

638 studies on the registry are indexed under Postoperative Nausea and Vomiting; 110 are open to participants now.

Browse Postoperative Nausea and Vomiting studies →

Open to participants now

22 of the 96 studies in Postoperative Nausea and Vomiting with a site in Turkey are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 66 Postoperative Nausea and Vomiting studies recruiting now, 22 (33%) set no upper age limit and 38 (58%) stop at 75 or younger; 15 take children under 18; 11 take healthy volunteers.

This study: 3 Years to 10 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 96 studies in Postoperative Nausea and Vomiting with a site in Turkey, or all of them as a file.
02

Study summary

Emergence delirium is a common complication in pediatric patients undergoing general anesthesia. The aim of this study is to investigate the incidence of postoperative awakening delirium and agitation in pediatric patients aged 3-10 years (ASA I-II) using two different target-controlled infusion (TCI) methods (Paedfusor and Eleveld) for TIVA, compared to inhalation anesthesia. This study will examine the effect of two different TCI models on postoperative awakening agitation/delirium by comparing them with each other and with inhalation anesthesia.

Read the detailed description

Postoperative emergence agitation/delirium (POED) is a postoperative complication in pediatric anesthesia and is characterized by perceptual and psychomotor impairment that negatively impacts postoperative recovery. According to the literature, inhalation anesthesia is associated with a higher incidence of ED compared to propofol-based anesthesia. In this study, we aimed to investigate the effect of two different TCI models, in which the depth of general anesthesia was monitored with BIS monitoring, on reducing the incidence of ED.

Both the Paedfusor and Eleveld models describe propofol pharmacokinetics via a three-compartment structure. These pharmacokinetic models are drug infusion models created by taking 600-10,000 blood samples at specific intervals after administering various doses of the drug to real patients and measuring the blood concentrations. They are used to provide a more stable and consistent level of total intravenous anesthesia.

Both models have been used for propofol infusion in pediatric anesthesia for many years. Differences exist between them in terms of distribution volume, elimination rate constant between compartments, and induction and maintenance phases depending on the characteristics of the pharmacokinetic model used. These models are already loaded onto perfusion devices in the operating room. Patient data such as height, weight, and gender are entered into the device, the target dose is determined by the clinician, and the device calculates the necessary dose for induction and maintenance according to the pharmacokinetic models.

This study was designed as a prospective, randomized, controlled, single-blind (evaluator-blind), three-arm clinical trial comparing the effects of total intravenous anesthesia and inhalation anesthesia, administered with two different target-controlled infusion (TCI) models (Paedfusor and Eleveld), on postoperative awakening agitation in pediatric patients aged 3-10 years with ASA I-II status and scheduled for elective urogenital surgery.

Participants will be randomly assigned to one of three groups: Paedfusor TCI, Eleveld TCI, or sevoflurane anesthesia. Standard monitoring and anesthesia protocols will be applied to all patients. Emergence delirium will be assessed using the Pediatric Anesthesia Emergence Delirium (PAED) scale, and postoperative pain will be evaluated using the FLACC scale.

Secondary outcomes include severity of emergence delirium, association between bispectral index (BIS)-derived alpha band power and ED, time to emergence, postoperative nausea and vomiting, duration of BIS suppression, and the need for additional sedation and analgesia.

This study aims to provide evidence on the optimal anesthetic approach to reduce emergence delirium in pediatric patients and to explore the neurophysiological correlates of ED using BIS monitoring

03

Conditions studied

  • Emergence Delirium in Pediatric Anesthesia
  • Pediatric Anesthesia
  • Postoperative Agitations in Pediatric Patients
  • Postoperative Nausea and Vomiting (PONV)

Keywords

  • pediatric anesthesia
  • paedfusor
  • eleveld
  • target controlled infusion
  • sevoflurane
  • postoperative agitation
04

Who can participate

Ages eligible
3 Years to 10 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children aged 3-10 years
  • Children weighing over 10 kg
  • (ASA) physical condition classification I-II
  • Those who will undergo planned urogenital surgery under general anesthesia
  • Those who have obtained written from their parents or legal guardians

Exclusion criteria

Exclusion Criteria:

  • Patients assessed as or higher
  • Known neurological or psychiatric disorders
  • Developmental delay or cognitive impairment
  • Use of sedatives or psychoactive drugs
  • Allergy or to the study drugs (propofol or sevoflurane)
  • History of previous adverse reactions to anesthesia
  • Patients requiring emergency surgery
  • Significant liver, kidney, or cardiovascular disease
  • Patients whose parents or legal guardians have not given consent
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Paedfusor Group

    Anesthesia will be maintained using propofol with target-controlled infusion based on the Paedfusor pharmacokinetic model.

    Drug: propofol ( Paedfusor Model)

  • Experimental
    Eleveld Group

    Anesthesia will be maintained using propofol with target-controlled infusion based on the Eleveld pharmacokinetic model.

    Drug: propofol (Eleveld Model)

  • Active comparator
    Sevoflurane Group

    Anesthesia will be maintained using sevoflurane inhalational anesthesia.

    Drug: Sevofluorane

Interventions

06

What researchers measure

Primary outcomes

  1. Emergence Delirium Assessed by PAED Scale

    Postoperative awakening delirium and its severity will be assessed using the Pediatric Anesthesia Awakening Delirium (PAED) scale.

    Time frame: Within the first 30 minutes after emergence from anesthesia

Secondary outcomes

  1. Postoperative Pain Assessed by FLACC Scale

    Postoperative pain will be assessed using the Face, Legs, Activity, Cry, Consolability (FLACC) scale.

    Time frame: Within the first 120 minutes after surgery

  2. Association Between BIS-Derived Alpha Band Power and Emergence Delirium

    The relationship between bispectral index (BIS)-derived alpha frequency band power and emergence delirium will be evaluated in patients who develop emergence delirium.

    Time frame: Intraoperative period

  3. Time to Emergence

    Time from discontinuation of anesthesia to eye opening and response to verbal stimuli.

    Time frame: Within the first 120 minutes after surgery

  4. Incidence of Postoperative Nausea and Vomiting

    Occurrence of nausea and/or vomiting in the postoperative period.

    Time frame: Within 30 minutes after the surgery

  5. Duration of BIS Suppression

    Total duration of electroencephalographic suppression periods as detected by BIS monitoring during anesthesia.

    Time frame: Intraoperative period

  6. Need for Additional Sedation

    Requirement for rescue sedative medication in the postoperative period.

    Time frame: 0-30 minutes postoperatively

  7. Need for Additional Analgesia

    Requirement for rescue analgesic medication in the postoperative period.

    Time frame: 0-30 minutes postoperatively

07

Study locations

2 of 2 sites recruiting
  • Marmara University Pendik Research and Training Hospital
    Istanbul, 34890, Turkey (Türkiye)
    Recruiting
  • Marmara University Pendik Research and Training Hospital
    Istanbul, 34890, Turkey (Türkiye)
    Recruiting
    • Rukiye Seyma Eslek, MD (Resident) · Contactseyma.eslek@gmail.com · +90 539 573 5400
    • Nazan Atalan Özlen · Principal investigator
    • Rukiye Seyma Eslek, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared due to privacy and ethical considerations, including the protection of personal health information.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Oct 2027, 20 months after the start.

Of 181 non-industry interventional studies with no phase under Postoperative Nausea and Vomiting, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 26. This study's planned 20 months is above that.

Counting every sponsor, half of 181 studies reached it within 13 months; a quarter within 5 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2026
First posted
Apr 16, 2026
StartActual
Jan 13, 2026
Primary completionEst.
Oct 1, 2027
CompletionEst.
Nov 30, 2027
Last update
Apr 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07534956
Lead sponsor
Marmara University Pendik Training and Research Hospital
Responsible party
dilara gocmen (Assist prof, Marmara University Pendik Training and Research Hospital) — Principal investigator
First posted
Apr 16, 2026
Start date
Jan 13, 2026
Primary completion
Oct 1, 2027 (estimated)
Completion
Nov 30, 2027 (estimated)
Last update
Apr 16, 2026

Study contacts

Rukiye Seyma Eslek
Contact
seyma.eslek@gmail.com
+90 539 573 5400

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Propofol

Start the discussion